Research published this week in the journal Molecular Pain details advances being made in understanding the cellular mechanisms underlying Painful Diabetic Neuropathy (PDN). PDN is a debilitating syndrome present in a quarter of diabetic patients with substantial adverse impact on their quality of life. Current therapies for PDN are only partially effective.
Chemokine signaling has been implicated in the pathogenesis of neuropathic pain in a variety of animal models. The study team tested the hypothesis that chemokine signaling mediates DRG neuronal hyperexcitability in association with PDN. They found that intraperitoneal administration of the specific CXCR4 antagonist AMD3100 reversed PDN in two animal models of type II diabetes. The authors conclude that targeting CXCR4 chemokine receptors may represent a novel intervention for treating PDN. Read the study abstract, with link to the full article, here.